VIP943 Generates Early Complete Responses, Is Safe in Advanced CD123+ Hematologic Malignancies
Complete responses were achieved by 2 patients with advanced CD123-positive hematologic malignancies who received VIP943 in a phase 1 study.
Complete responses were achieved by 2 patients with advanced CD123-positive hematologic malignancies who received VIP943 in a phase 1 study.
LMP744 has been granted orphan drug designation by the FDA for the treatment of patients with glioma.
Nature – A population of tumour-specific PD1+TCF1+ CD4 T cells in tumour-draining lymph nodes is capable of self-renewal and differentiation into CD4 effector cells, thereby…
Nature Reviews Cancer – Immunotherapy shows promise in treating cancers by engineering T cells or using antibodies to activate them. However, cancer stem cells (CSCs)…
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Sarah Sammons, MD, discusses some of the problems seen with brain metastasis in HER2-positive metastatic breast cancer.
Novel agents such as belantamab mafodotin may improve PFS in patients with relapsed MM after anti-CD38 treatment.
CE certification was granted to the VENTANA CDLN18 RxDx assay for the assessment of CLDN18 protein expression in gastric or GEJ adenocarcinoma in Europe.
An abstract is unavailable.
Myxoid liposarcoma is a rare cancer that develops in fat cells. It accounts for about 30% to 40% of liposarcoma cases. Here, I’ll discuss myxoid…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.